Returns from Strategies Adopted by MNEs to Improve Global Health and Wellbeing: Third Sustainable Development Goal

Abstract

Intentions of managers of pharmaceutical multinational enterprises (MNEs) to adopt business strategies, which will aid global health and wellbeing, are in some ways linked with their understanding of the returns that their company will receive from these investments. However, the MNE’s managers are unaware of business strategies that will allow them to link their business activities with the corporate objectives of contributing to Sustainable Development Goals (SDGs). Pharmaceutical companies are moving toward monopolistic practices by acquiring local companies for manufacturing purposes or by engaging local companies in contract manufacturing and directing the focus of these companies away from innovation and toward profit making. At the same time, pharmaceutical MNEs are promoting global health and wellbeing as their SDGs. This study uses knowledge from existing sources and expert insights to explain the returns that MNEs can get from their investments related to global health and wellbeing. One of the important recommendations from the ethical point of view is engaging local firms in the innovation process; from the marketing perspective, this study recommends the use of a corporate brand and not a product brand for offering generic medicines. The operations perspective explains how MNEs can incorporate the social agenda into their mainstream business strategies. Limitations of the study are discussed, and avenues for future research are explained.

Citation

Gupta, S. (2017), "Returns from Strategies Adopted by MNEs to Improve Global Health and Wellbeing: Third Sustainable Development Goal", Multinational Enterprises and Sustainable Development (International Business and Management, Vol. 33), Emerald Publishing Limited, Leeds, pp. 151-172. https://doi.org/10.1108/S1876-066X20170000033007